Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: A randomized placebo-controlled trial*

Honeycutt, Travis; Khashab, Mohamed El; Wardrop, Richard M.; McNeal-Trice, Kenya; Honeycutt, Andrea L; Christy, Claudia G.; Mistry, Kshitij P.; Harris, Bradford D.; Meliones, Jon N.; Kocis, Keith C.

doi:10.1097/01.pcc.0000282176.41134.e6

Cited by 109 publications

(71 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…37 Another recent study found no significant effect in pediatric ICU patients. 38 Published case reports have raised concerns about the safety of probiotics in critically ill patients. [39][40][41][42][43][44] Because probiotics are, by definition, indigenous to the human gut, it may be impossible to establish a definite causal link between probiotic supplementation and Lactobacillus bacteremia.…”

Section: Discussionmentioning

confidence: 99%

Lactobacillus GG as Treatment for Diarrhea During Enteral Feeding in Critical Illness

Ferrie

Daley

2010

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Background: Diarrhea is a common problem in critical illness. The aim of this study was to investigate the effect of probiotic treatment with Lactobacillus rhamnosus GG on established diarrhea in critically ill patients. Methods: This prospective randomized blinded trial in the adult intensive care unit of a large tertiary referral teaching hospital compared probiotic treatment with placebo. Thirty‐six consecutive critically ill enterally fed adults with diarrhea were randomized to receive 2 capsules per day for 7 days of either Lactobacillus GG in an inulin base (Culturelle) or inulin alone (placebo). Diarrhea was defined as ≥3 unformed stools or >200 mL stool volume within 24 hours. Prospectively defined primary end point was duration of diarrhea, and secondary end point was mean number of loose stools per day during the 14 days from the first capsule. Results by intention‐to‐treat analysis: No significant difference was observed for any end point. There was a trend toward more diarrhea in the probiotic treatment group. Mean (standard deviation) duration of diarrhea was 3.83 (2.39) days for the probiotic group and 2.56 (1.85) days for the placebo group (P = .096). Mean number of loose stools per day during the 14 days from the first capsule was 1.58 (0.88) in the probiotic group and 1.10 (0.79) in the placebo group (P = .150). Conclusions: This study does not support the use of Lactobacillus GG as a treatment for established diarrhea in enterally fed critically ill patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Lactobacillus GG as Treatment for Diarrhea During Enteral Feeding in Critical Illness

Ferrie

Daley

2010

J Parenter Enteral Nutr

View full text Add to dashboard Cite

show abstract

“…[155]. A study in a pediatric unit even reported a trend toward an increase in nosocomial throughout a probiotic supplementation [156] although a routinary supplementation of VLBW infants with a probiotics strains over a 6-year period was safe [157].…”

Section: Probiotics In Preterm Neonatesmentioning

confidence: 99%

Usefulness of Probiotics for Neonates?

Butel¹,

Waligora‐Dupriet²,

Aires³

2012

Probiotics

View full text Add to dashboard Cite

“…Many outcome measures were reported in different trials on children (Rio et al, 2002;Sanz et al, 2006;Rautava et al, 2009;Hojsak et al, 2010;Merenstein et al, 2010;Rerksuppaphol and Rerksuppaphol, 2012). Honeycutt et al (2007) conducted a randomized, placebo-controlled trial, using L. rhamnosus strain GG that was not shown to be effective in reducing the incidence of nosocomial infections (Honeycutt et al, 2007).…”

Section: Author(s) Agree That This Article Remains Permanently Open Amentioning

confidence: 99%

Role of probiotics in prevention of hospital acquired pneumonia in Egyptian children admitted to Pediatric Intensive Care Unit of Mansoura University Childrens Hospital

El‐Wakeel¹,

El-Wakeel²,

El-Assmy³

et al. 2016

Afr. J. Microbiol. Res.

View full text Add to dashboard Cite

The objective of the study is to evaluate the effect of probiotics to reduce the risk of hospital-acquired pneumonia in Pediatric Intensive Care Unit. The study is a double-blinded randomized placebocontrolled study. Patients were evenly and randomly assigned in two groups. The first group was 50 randomly selected patients who formed the placebo group, while the second group was 70 patients selected randomly to form the intervention group that received the probiotic capsules; Lactobacillus rhamnosus strain GG, once a day. The study site was Pediatric Intensive Care Unit in a universityaffiliated children's hospital. Fifteen (30%) patients in the placebo population developed hospitalacquired pneumonia. Of the 15 patients, infections in 22% were caused by Gram-negative organisms. In the intervention group, 10% developed hospital-acquired pneumonia. The causative agents were predominantly Gram-negative organisms (22% Gram-negative vs. 7% Gram-positive; P-value; 0.01). After 72 h of study, significantly higher oral and gastric colonization rates were observed in patients who were given placebo treatment, compared with those given Lactobacilli. The current study is the first to report these higher significant variations. The current study found an influence of probiotic supplementation on the rate of hospital-acquired pneumonia.

show abstract

Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: A randomized placebo-controlled trial*

Cited by 109 publications

References 62 publications

Lactobacillus GG as Treatment for Diarrhea During Enteral Feeding in Critical Illness

Lactobacillus GG as Treatment for Diarrhea During Enteral Feeding in Critical Illness

Usefulness of Probiotics for Neonates?

Role of probiotics in prevention of hospital acquired pneumonia in Egyptian children admitted to Pediatric Intensive Care Unit of Mansoura University Childrens Hospital

Contact Info

Product

Resources

About